Since the turn of the millennium, antibody-drug conjugates (ADCs) have come to occupy a substantial niche in the world of targeted cancer treatments, with 14 ADCs approved to treat several cancer types by the U.S. Food and Drug Administration (FDA) at the time of this writing.
An